Skip to main content

Take action against Alzheimer’s

Do you want to take action against Alzheimer’s, just like me? See below the full overview of our studies.

What we’ve achieved so far

75+

Trials

250+

Participants

3

Locations

Our Alzheimer’s trials

Filter

Alzheimer's

PRImus AD

The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.

audience55 - 80 years

levelMCI or a mild form of dementia caused by Alzheimer’s disease

durationApproximately 1 to 2 years

locationAmsterdam, Den Bosch or Zwolle

Alzheimer's

Celia

The goal of this study is to evaluate how safe and effective the new drug BIIB080 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug BIIB080 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is injected into the back.

audience50 - 80 years

levelMild to moderate Alzheimer’s disease

durationApproximately 2 years

locationAmsterdam

Alzheimer's

IBC-01-01

The goal of this study is to evaluate how safe, tolerable and effective the new drug IBC-Ab002 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug IBC-Ab002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an intravenous (IV) injection.

audience50-80 years

levelEarly stage Alzheimer's disease

duration54 weeks

locationAmsterdam

Alzheimer's

GemVax

The goal of this study is to evaluate how safe and effective the new drug GV1001 is for the treatment of participants with mild to moderate stage Alzheimer’s Disease. The study compares the effect of the new drug GV1001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through a subcutaneous injection.

audience55 - 85 years

levelMild to moderate stage Alzheimer’s disease

duration58 weeks

locationAmsterdam, Den Bosch and Zwolle

Alzheimer's

Treeway

The goal of this study is to evaluate how safe and effective the new drug TW001 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug TW001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug consists of granules which are dissolved in water.

audience55 - 80 years

levelEarly stage Alzheimer's disease

durationApproximately 17 weeks

locationAmsterdam, Den Bosch and Zwolle

Alzheimer's

Alnylam

The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.

audience18+

level MCI or mild dementia due to early onset Alzheimer’s disease

durationup to 14 months (with potential extension of up to additional 24 months)

locationAmsterdam

Let us know how we can help you

Do you have any questions or would you like to know more about one of our studies? Contact us by phone or email. We are happy to help you.

What do our participants say?

“The most important thing is that there is a solution.”

“With my participation, I may also help others,” says Mr. Arts, one of our participants.

Our partners

Our mission is to eliminate brain diseases, but we cannot do that alone. That is why we work together with leading partners.